Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-242-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.97 million
Profitability
Miscellaneous
Employees41
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) issued its earnings results on Thursday, May, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.78) by $0.49. The firm had revenue of $7.72 million for the quarter, compared to analyst estimates of $1.25 million. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. View Spero Therapeutics' Earnings History.
When is Spero Therapeutics' next earnings date?
What price target have analysts set for SPRO?
3 brokerages have issued 1-year price targets for Spero Therapeutics' stock. Their forecasts range from $9.00 to $30.00. On average, they anticipate Spero Therapeutics' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.
What is the consensus analysts' recommendation for Spero Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019)
- 2. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (3/20/2019)
Has Spero Therapeutics been receiving favorable news coverage?
Media stories about SPRO stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spero Therapeutics earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Spero Therapeutics.
Are investors shorting Spero Therapeutics?
Spero Therapeutics saw a decline in short interest in the month of May. As of May 31st, there was short interest totalling 247,800 shares, a decline of 6.6% from the April 30th total of 265,200 shares. Based on an average daily trading volume, of 74,300 shares, the short-interest ratio is presently 3.3 days. Currently, 2.5% of the shares of the stock are short sold. View Spero Therapeutics' Current Options Chain.
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include Cara Therapeutics (CARA), Rhythm Pharmaceuticals (RYTM), Mallinckrodt (MNK), Vanda Pharmaceuticals (VNDA), Axsome Therapeutics (AXSM), CannTrust (CNTTF), Y-mAbs Therapeutics (YMAB), Kiniksa Pharmaceuticals (KNSA), Advanz Pharma (CXRXF), MacroGenics (MGNX), Emisphere Technologies (EMIS), Eagle Pharmaceuticals (EGRX), Odonate Therapeutics (ODT), Kura Oncology (KURA) and G1 Therapeutics (GTHX).
What other stocks do shareholders of Spero Therapeutics own?
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
- Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)
- Ms. Cristina Larkin, Chief Operating Officer (Age 49)
- Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
Who are Spero Therapeutics' major shareholders?
Spero Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.22%), Fosun International Ltd (0.59%), Virtu Financial LLC (0.06%) and Marshall Wace LLP (0.02%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.
Which institutional investors are selling Spero Therapeutics stock?
SPRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Fosun International Ltd. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Cristina Larkin and Joel Sendek. View Insider Buying and Selling for Spero Therapeutics.
Which institutional investors are buying Spero Therapeutics stock?
SPRO stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Marshall Wace LLP. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $11.97.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $209.76 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe.View Additional Information About Spero Therapeutics.
What is Spero Therapeutics' official website?
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
